Influence of Butyrate on Impaired Gene Expression in Colon from Patients with High Blood Pressure
Open Access
- 31 January 2023
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (3) , 2650
Abstract
Hypertension (HTN) is associated with gut dysbiosis and the depletion of butyrate-producing bacteria in animal models and people. Furthermore, fecal material transfer from donor hypertensive patients increases blood pressure in normotensive recipient animals and ameliorates HTN-associated pathophysiology. These observations have implications in the impaired interactions between the gut and gut microbiota in HTN. Although this concept is supported in animal models, little is known about human HTN. Therefore, our objective for this study was to compare gene expression with transcriptomics and its potential to influence microbiota in subjects with normal and high blood pressure (HBP). Colon samples from reference subjects with normal blood pressure (REF) and HBP were used for RNA-seq to analyze their transcriptomes. We observed the significant downregulation of gene sets governing immune responses (e.g., SGK1 and OASL), gut epithelial function (e.g., KRT20 and SLC9A3R1), gut microbiota (e.g., PPARG and CIDEC) and genes associated with cardiovascular and gut diseases (e.g., PLAUR and NLN) in HBP subjects; the expression of genes within these pathways correlated with blood pressure. Potential drug targets in the gut epithelium were identified using the Drug Gene International Database for possible use in HTN. They include peroxisome proliferator-activated receptor gamma (PPRG), active serum/glucocorticoid regulated kinase 1 (SGK1) and 3 beta-hydroxysteroid isomerase type II inhibitor (HSD3B). Finally, butyrate, a microbiota-derived short-chain fatty acid, restored the disrupted expression of certain functional genes in colonic organoids from HBP subjects. Patients with HBP exhibit a unique transcriptome that could underlie impaired gut–microbiota interactions. Targeting these interactions could provide a promising new therapeutic intervention for hypertension management.Keywords
Funding Information
- National Institutes of Health National Heart, Lung, and Blood Institute (HL033610, HL110170, HL132448)
This publication has 59 references indexed in Scilit:
- The role of short-chain fatty acids in the interplay between diet, gut microbiota, and host energy metabolismJournal of Lipid Research, 2013
- MYADM controls endothelial barrier function through ERM-dependent regulation of ICAM-1 expressionMolecular Biology of the Cell, 2013
- Olfactory receptor responding to gut microbiota-derived signals plays a role in renin secretion and blood pressure regulationProceedings of the National Academy of Sciences, 2013
- Circulating soluble urokinase plasminogen activator receptor predicts cancer, cardiovascular disease, diabetes and mortality in the general populationJournal of Internal Medicine, 2010
- Butyrate Enhances the Intestinal Barrier by Facilitating Tight Junction Assembly via Activation of AMP-Activated Protein Kinase in Caco-2 Cell MonolayersThe Journal of Nutrition, 2009
- Butyrate Improves Insulin Sensitivity and Increases Energy Expenditure in MiceDiabetes, 2009
- CEACAM1: contact-dependent control of immunityNature Reviews Immunology, 2006
- Keratin 20 Serine 13 Phosphorylation Is a Stress and Intestinal Goblet Cell MarkerJournal of Biological Chemistry, 2006
- 17β-Hydroxysteroid dehydrogenase type 9 and other short-chain dehydrogenases/reductases that catalyze retinoid, 17β- and 3α-hydroxysteroid metabolismMolecular and Cellular Endocrinology, 2001
- Elevated fibrinogen and plasminogen activator inhibitor (PAI‐1) in hypertension are related to metabolic risk factors for cardiovascular diseaseJournal of Internal Medicine, 1990